Solana (HSDT) Projected to Announce Quarterly Earnings on Thursday

Solana (NASDAQ:HSDT) is projected to release its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $3.50 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 21, 2026 at 4:00 PM ET.

Solana (NASDAQ:HSDT) last posted its quarterly earnings data on Friday, May 15th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.96). The business had revenue of $3.62 million during the quarter, compared to the consensus estimate of $3.40 million. Solana had a negative net margin of 1,427.15% and a negative return on equity of 67.57%. On average, analysts expect Solana to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Solana Trading Up 0.6%

NASDAQ HSDT opened at $1.70 on Tuesday. The firm has a market capitalization of $99.26 million, a price-to-earnings ratio of -0.02 and a beta of 1.01. The firm’s 50 day simple moving average is $1.65 and its 200 day simple moving average is $1.98. Solana has a 1 year low of $1.19 and a 1 year high of $25.50.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD purchased a new position in shares of Solana during the fourth quarter valued at approximately $46,000. OMERS ADMINISTRATION Corp purchased a new stake in Solana in the 4th quarter valued at $88,000. Aristides Capital LLC bought a new position in Solana during the 4th quarter valued at $137,000. XTX Topco Ltd bought a new position in Solana during the 4th quarter valued at $140,000. Finally, Marshall Wace LLP purchased a new position in Solana during the 4th quarter worth $195,000. 18.63% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

HSDT has been the subject of several research reports. Zacks Research upgraded Solana to a “hold” rating in a research report on Monday, April 27th. B. Riley Financial initiated coverage on Solana in a report on Thursday, April 23rd. They set a “buy” rating and a $3.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Solana in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Solana presently has a consensus rating of “Moderate Buy” and an average price target of $3.50.

Solana Company Profile

Helius Medical Technologies, Inc (NASDAQ: HSDT) is a medical technology company focused on developing and commercializing non‐invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.

The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics.